Skip to content

Amprius Technologies AMPX Government grants

Government grants at other companies

Addus HomeCare logo
Addus HomeCareADUS
$14.64M+68.2%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$6.34M
Amprius Technologies logo
Amprius TechnologiesAMPX
$2.74M
ICU Medical logo
ICU MedicalICUI
$4.77M-30.2%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$176.11M+12.0%
Micron Technology logo
Micron TechnologyMU
$1B+19.9%

Other financials

Income statement

See full
Revenue$28.5M+153%
Gross profit$5.7M+343%
Operating income-$6.7M+30.9%
Net income-$5.0M+46.2%
EPS (diluted)-$0.04+50.0%

Balance sheet

See full
Cash & equivalents$62.6M+25.5%
Total debt$6.6M-82.6%
Total equity$109.4M+55.4%
Total assets$130.8M+10.4%

Cash flow

See full
Operating cash flow-$37.3M-164%
CapEx$980.0K+7.3%
Free cash flow-$38.3M-154%

Valuation

See full
Market cap$2B+631%
Enterprise value$1.94B+642%
P/S22.2×+13.9×

Profitability

See full
Gross margin18.1%+10.5pp
Operating margin-48.4%-19.0pp
Net margin-44%-17.6pp
FCF margin-65.1%-19.6pp

Returns & leverage

See full
Return on equity-44.2%-11.4pp
Debt / equity0.1×-0.5×
Current ratio7.1×+2.4×

Where this comes from

Reported directly by Amprius Technologies in its filing.

Tagged under the XBRL concept us-gaap:GovernmentAssistanceLiabilityCurrent.

The official record: Amprius Technologies’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amprius Technologies's government grants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amprius Technologies's government grants?
Amprius Technologies (AMPX) reported government grants of $2.74M in Q1 2026.
What does government grants mean?
This metric represents the current portion of financial assistance, subsidies, or grant funding received from government entities that is subject to specific performance conditions or repayment obligations. It reflects the company's reliance on public sector support to fund research, development, or operational activities within the next twelve months. Monitoring this balance helps investors assess the company's exposure to government policy changes and the potential impact of grant-related obligations on short-term liquidity.